Unity Biotechnology Inc Total Assets
Unity Biotechnology Inc total assets. Based on the latest financial reports, Unity Biotechnology Inc (UBX) holds total assets worth $30.35 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Unity Biotechnology Inc market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Unity Biotechnology Inc (2016–2024)
Total assets of Unity Biotechnology Inc from 2016 to 2024. This chart illustrates how Unity Biotechnology Inc's total assets have evolved over time, based on quarterly financial data. See latest Unity Biotechnology Inc stock price today for real-time trading data and today's change.
Unity Biotechnology Inc - Asset Composition Analysis
Unity Biotechnology Inc Total Assets Breakdown (December 2024)
Unity Biotechnology Inc total assets breakdown as of December 2024. Unity Biotechnology Inc's total assets of $30.35 Million consist of 64.4% current assets and 35.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Unity Biotechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore UBX net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Unity Biotechnology Inc's current assets represent 64.4% of total assets in 2024, a decrease from 96.7% in 2016.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2024, down from 92.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Unity Biotechnology Inc Competitors by Total Assets
Key competitors of Unity Biotechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Unity Biotechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.95 | 4.98 | 7.88 |
| Quick Ratio | 1.95 | 4.98 | 7.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.58 Million | $30.79 Million | $107.87 Million |
Unity Biotechnology Inc - Advanced Valuation Insights
This section examines the relationship between Unity Biotechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.59 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -42.7% |
| Total Assets | $37.66 Million |
| Market Capitalization | $2.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Unity Biotechnology Inc's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Unity Biotechnology Inc's assets decreased by 42.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Unity Biotechnology Inc (2016–2024)
The table below shows the annual total assets of Unity Biotechnology Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $37.66 Million | -42.67% |
| 2023-12-31 | $65.69 Million | -47.17% |
| 2022-12-31 | $124.35 Million | -0.29% |
| 2021-12-31 | $124.71 Million | -20.22% |
| 2020-12-31 | $156.32 Million | +3.37% |
| 2019-12-31 | $151.22 Million | -16.63% |
| 2018-12-31 | $181.38 Million | +77.78% |
| 2017-12-31 | $102.02 Million | +5.56% |
| 2016-12-31 | $96.65 Million | -- |
About Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develop… Read more